Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy
- 23 December 2008
- journal article
- review article
- Published by Wiley in Molecular Nutrition & Food Research
- Vol. 53 (1) , 87-103
Abstract
The thioredoxin (Trx) system is a major antioxidant system integral to maintaining the intracellular redox state. It contains Trx, a redox active protein, which regulates the activity of various enzymes including those that function to counteract oxidative stress within the cell. Trx can also scavenge reactive oxygen species (ROS) and directly inhibits proapoptotic proteins such as apoptosis signal‐regulating kinase 1 (ASK1). The oxidized form of Trx is reduced by thioredoxin reductase (TrxR). The cytoplasm and mitochondria contain equivalent Trx systems and inhibition of either system can lead to activation of apoptotic signaling pathways. There are a number of inhibitors with chemotherapy applications that target either Trx or TrxR to induce apoptosis in cancer cells. Suberoylanilide hydroxamic acid (SAHA) is effective against many cancer cells and functions by up‐regulating an endogenous inhibitor of Trx. Other compounds target the selenocysteine‐containing active site of TrxR. These include gold compounds, platinum compounds, arsenic trioxide, motexafin gadolinium, nitrous compounds, and various flavonoids. Inhibition of TrxR leads to an accumulation of oxidized Trx resulting in cellular conditions that promote apoptosis. In addition, some compounds also convert TrxR to a ROS generating enzyme. The role of Trx system inhibitors in cancer therapy is discussed in this review.Keywords
This publication has 121 references indexed in Scilit:
- Thioredoxin and TRAF Family Proteins Regulate Reactive Oxygen Species-Dependent Activation of ASK1 through Reciprocal Modulation of the N-Terminal Homophilic Interaction of ASK1Molecular and Cellular Biology, 2007
- Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxideProceedings of the National Academy of Sciences, 2007
- Thioredoxin is required for S-nitrosation of procaspase-3 and the inhibition of apoptosis in Jurkat cellsProceedings of the National Academy of Sciences, 2007
- Thioredoxin in cancer—Role of histone deacetylase inhibitorsSeminars in Cancer Biology, 2006
- Mitochondrial thioredoxin in regulation of oxidant‐induced cell deathFEBS Letters, 2006
- Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitorProceedings of the National Academy of Sciences, 2006
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005
- Interactions of Selected Gold(III) Complexes with Calf Thymus DNABiochemical and Biophysical Research Communications, 2001
- Induction of Apoptosis by ASK1, a Mammalian MAPKKK That Activates SAPK/JNK and p38 Signaling PathwaysScience, 1997
- Efficient Reduction of Lipoamide and Lipoic Acid by Mammalian Thioredoxin ReductaseBiochemical and Biophysical Research Communications, 1996